NCT06948032View on ClinicalTrials.gov

Study of BLU-808 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

January 21, 2025

Study Completion Date

January 21, 2025

Conditions
Healthy Participants
Interventions
DRUG

BLU-808

BLU-808 will be administered per schedule specified in the arm description.

DRUG

Placebo

BLU-808 matching placebo will be administered per schedule specified in the arm description.

DRUG

Midazolam

Midazolam will be administered per schedule specified in the arm description.

Trial Locations (1)

68502

Celerion, Inc., Lincoln

Sponsors
All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY

NCT06948032 - Study of BLU-808 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter